{"id":"high-dose-amoxicillin-clavulanate","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Diarrhea"},{"rate":"5-10","effect":"Nausea"},{"rate":"3-5","effect":"Vomiting"},{"rate":"3-5","effect":"Rash"},{"rate":"3-5","effect":"Abdominal pain"},{"rate":"1-3","effect":"Allergic reaction"},{"rate":"1-2","effect":"Clostridium difficile-associated diarrhea"}]},"_chembl":{"chemblId":"CHEMBL2105950","moleculeType":"Small molecule","molecularWeight":"387.39"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Amoxicillin is a beta-lactam antibiotic that disrupts peptidoglycan cross-linking in bacterial cell walls, leading to cell lysis and death. Clavulanate is a beta-lactamase inhibitor that protects amoxicillin from enzymatic degradation by resistant bacteria, extending the spectrum of activity against beta-lactamase-producing organisms. High-dose formulations increase drug exposure to treat serious infections and overcome certain resistance mechanisms.","oneSentence":"Amoxicillin inhibits bacterial cell wall synthesis by binding penicillin-binding proteins, while clavulanate inhibits beta-lactamase enzymes to prevent antibiotic degradation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:47:39.225Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial infections caused by beta-lactamase-producing organisms (respiratory tract, urinary tract, skin and soft tissue infections)"},{"name":"Otitis media"},{"name":"Sinusitis"},{"name":"Community-acquired pneumonia"}]},"trialDetails":[{"nctId":"NCT07236944","phase":"PHASE4","title":"Pivmecillinam as Oral Step-Down Treatment for Escherichia Coli Febrile Urinary Tract Infection Versus Standard of Care","status":"RECRUITING","sponsor":"Uppsala University","startDate":"2025-12","conditions":"Febrile Urinary Tract Infection","enrollment":560},{"nctId":"NCT06443502","phase":"PHASE3","title":"A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic Pouchitis","status":"RECRUITING","sponsor":"Takeda","startDate":"2024-11-19","conditions":"Pouchitis","enrollment":30},{"nctId":"NCT04563325","phase":"PHASE4","title":"Oral-only Antibiotics for Bone and Joint Infections in Children","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2020-09-15","conditions":"Osteomyelitis, Septic Arthritis, Bone Infection","enrollment":180},{"nctId":"NCT06827496","phase":"","title":"Initial Oral Antibiotics for Bone and Joint Infections in Children","status":"RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2024-11-15","conditions":"Osteomyelitis Acute, Septic Arthritis, Bone Infection","enrollment":100},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT05819229","phase":"","title":"Oral Antibiotics Alone in Children Aged 4 Weeks to 2 Months With a Urinary Tract Infection","status":"RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2023-02-27","conditions":"Urinary Tract Infections in Children","enrollment":125},{"nctId":"NCT03237182","phase":"PHASE4","title":"The Individualized M(X) Drug-resistant TB Treatment Strategy Study","status":"TERMINATED","sponsor":"Centre for the AIDS Programme of Research in South Africa","startDate":"2017-06-14","conditions":"Tuberculosis, Multidrug-Resistant","enrollment":205},{"nctId":"NCT05308849","phase":"NA","title":"Peritoneal Diffusion and Efficacy of Antibiotic Therapy in Pediatric Peritonitis","status":"UNKNOWN","sponsor":"Central Hospital, Nancy, France","startDate":"2022-03-31","conditions":"Peritonitis, Appendicitis, Children, Only","enrollment":41},{"nctId":"NCT03431337","phase":"PHASE4","title":"Treatment of Acute Sinusitis With High-Dose vs. Standard-Dose Amoxicillin/Clavulanate","status":"TERMINATED","sponsor":"Paul Sorum, MD","startDate":"2018-02-26","conditions":"Sinusitis, Acute","enrollment":157},{"nctId":"NCT04378231","phase":"NA","title":"Higher Versus Standard Dose of Amoxicillin-clavulanate in Pediatric PBB","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Wenzhou Medical University","startDate":"2020-05","conditions":"Protracted Bacterial Bronchitis","enrollment":100},{"nctId":"NCT01166945","phase":"NA","title":"Short (5 Days) Versus Long (14 Days) Duration of Antimicrobial Therapy for Acute Bacterial Sinusitis in Children","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2010-11","conditions":"Sinusitis","enrollment":98},{"nctId":"NCT02340000","phase":"PHASE4","title":"Clinical Trial of the Treatment of Acute Sinusitis With Standard-dose Versus High-dose Amoxicillin/Clavulanate","status":"COMPLETED","sponsor":"Albany Medical College","startDate":"2014-11-18","conditions":"Sinusitis","enrollment":315},{"nctId":"NCT00332163","phase":"PHASE2","title":"Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-04","conditions":"Metastatic Colorectal Cancer, Skin Rash, Skin Toxicities","enrollment":95},{"nctId":"NCT01559753","phase":"PHASE4","title":"Early-onset Ventilator-associated Pneumonia in Adults: Comparison of 8 Versus 15 Days of Antibiotic Treatment","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"1998-01","conditions":"Pneumonia Ventilator Associated","enrollment":225},{"nctId":"NCT00643292","phase":"PHASE3","title":"A Single, High-Dose Azithromycin Extended Release (60 mg/kg) Compared With 10 Days of High-Dose Amoxicillin Clavulanate in Children With Ear Infections at High Risk of Persistent/Recurrent Ear Infections","status":"COMPLETED","sponsor":"Pfizer","startDate":"2003-01","conditions":"Acute Otitis Media","enrollment":902},{"nctId":"NCT00042718","phase":"PHASE3","title":"A Study of the Effectiveness and Safety of High Dose, Short-course Levofloxacin in the Treatment of Acute Bacterial Exacerbation (Worsening) of Chronic Bronchitis.","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2001-11","conditions":"Bronchitis, Chronic Bronchitis","enrollment":659}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":30,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"high dose amoxicillin/clavulanate","genericName":"high dose amoxicillin/clavulanate","companyName":"Albany Medical College","companyId":"albany-medical-college","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Amoxicillin inhibits bacterial cell wall synthesis by binding penicillin-binding proteins, while clavulanate inhibits beta-lactamase enzymes to prevent antibiotic degradation. Used for Bacterial infections caused by beta-lactamase-producing organisms (respiratory tract, urinary tract, skin and soft tissue infections), Otitis media, Sinusitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}